Free Trial

Hyperion DeFi (HYPD) Competitors

Hyperion DeFi logo
$7.74 -0.34 (-4.21%)
As of 04:00 PM Eastern

HYPD vs. AVTX, VOR, IPHA, CHRS, DERM, BIOA, APLT, BHST, ACTU, and PLX

Should you be buying Hyperion DeFi stock or one of its competitors? The main competitors of Hyperion DeFi include Avalo Therapeutics (AVTX), Vor Biopharma (VOR), Innate Pharma (IPHA), Coherus Oncology (CHRS), Journey Medical (DERM), BioAge Labs (BIOA), Applied Therapeutics (APLT), BioHarvest Sciences (BHST), Actuate Therapeutics (ACTU), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry.

Hyperion DeFi vs. Its Competitors

Avalo Therapeutics (NASDAQ:AVTX) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Avalo Therapeutics has higher revenue and earnings than Hyperion DeFi.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalo Therapeutics$441K523.99-$35.13MN/AN/A
Hyperion DeFi$60K897.84-$49.82M-$58.40-0.13

In the previous week, Avalo Therapeutics had 1 more articles in the media than Hyperion DeFi. MarketBeat recorded 1 mentions for Avalo Therapeutics and 0 mentions for Hyperion DeFi. Avalo Therapeutics' average media sentiment score of 0.19 beat Hyperion DeFi's score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Avalo Therapeutics Neutral
Hyperion DeFi Neutral

Avalo Therapeutics has a net margin of 0.00% compared to Hyperion DeFi's net margin of -62,238.41%. Avalo Therapeutics' return on equity of -48.48% beat Hyperion DeFi's return on equity.

Company Net Margins Return on Equity Return on Assets
Avalo TherapeuticsN/A -48.48% -35.94%
Hyperion DeFi -62,238.41%-876.25%-181.67%

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 3.0% of Avalo Therapeutics shares are held by company insiders. Comparatively, 10.9% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Avalo Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.

Avalo Therapeutics presently has a consensus price target of $31.67, suggesting a potential upside of 80.23%. Hyperion DeFi has a consensus price target of $2.00, suggesting a potential downside of 74.16%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Avalo Therapeutics is more favorable than Hyperion DeFi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
Hyperion DeFi
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

Summary

Avalo Therapeutics beats Hyperion DeFi on 11 of the 14 factors compared between the two stocks.

Get Hyperion DeFi News Delivered to You Automatically

Sign up to receive the latest news and ratings for HYPD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HYPD vs. The Competition

MetricHyperion DeFiBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$53.87M$219.08M$6.15B$10.77B
Dividend YieldN/A3.81%5.71%4.83%
P/E Ratio-0.133.2429.7228.55
Price / Sales897.845,399.10499.21189.70
Price / CashN/A13.1936.6160.67
Price / Book-0.0190.1012.016.61
Net Income-$49.82M-$90.99M$3.32B$276.82M
7 Day Performance6.46%0.30%1.54%1.96%
1 Month Performance-19.46%3.84%6.10%2.53%
1 Year Performance-81.29%555.79%61.10%32.80%

Hyperion DeFi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HYPD
Hyperion DeFi
0.2908 of 5 stars
$7.74
-4.2%
$2.00
-74.2%
-81.1%$53.87M$60K-0.1340
AVTX
Avalo Therapeutics
2.7987 of 5 stars
$17.08
+11.3%
$31.67
+85.4%
+58.6%$201.88M$441K0.0040
VOR
Vor Biopharma
2.6901 of 5 stars
$29.43
+1.5%
$77.83
+164.5%
N/A$198.76MN/A-0.11140Analyst Forecast
Insider Trade
IPHA
Innate Pharma
2.0682 of 5 stars
$2.12
-1.4%
$6.50
+206.6%
+13.5%$198.20M$21.77M0.00220
CHRS
Coherus Oncology
4.0953 of 5 stars
$1.79
+8.5%
$4.51
+152.1%
+106.2%$191.77M$266.96M1.15330News Coverage
Analyst Forecast
DERM
Journey Medical
1.4558 of 5 stars
$7.23
+0.4%
$12.17
+68.3%
+26.1%$189.43M$56.13M-19.0390News Coverage
Analyst Forecast
BIOA
BioAge Labs
0.0842 of 5 stars
$5.36
+3.5%
N/AN/A$185.70MN/A0.00N/A
APLT
Applied Therapeutics
3.5808 of 5 stars
$1.47
+14.8%
$4.13
+180.6%
-84.7%$184.34M$460K-3.2730
BHST
BioHarvest Sciences
2.0488 of 5 stars
$11.28
+2.1%
$13.67
+21.2%
N/A$181.46M$30.19M-16.11N/AAnalyst Forecast
Short Interest ↑
Gap Up
ACTU
Actuate Therapeutics
1.3547 of 5 stars
$7.39
-1.2%
$20.33
+175.1%
-4.1%$173.86MN/A0.0010News Coverage
Analyst Forecast
PLX
Protalix BioTherapeutics
2.1011 of 5 stars
$2.14
+15.1%
$15.00
+600.9%
+126.5%$170.63M$61.95M-16.46200

Related Companies and Tools


This page (NASDAQ:HYPD) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners